Biomagnetics Diagnostics Corp. is an advanced medical device and biotechnology company with a revolutionary diagnostics system and test kit testing technology for HIV, Hepatitis, H-Pylori, HPV, Tuberculosis and many other viruses, bacterium’s, toxins and diseases. The company focuses on real-time testing for the actual presence of the virus/ toxin/ disease itself, instead of the antibodies produced by the body’s immune system which may take anywhere from weeks to months to appear.

The company intends to follow the lead of established Western drugmakers and biotechs Merck & Co. (MRK), Wyeth (WYE), Eli Lilly & Co. (LLY), Schering-Plough (SGP), Novartis (NVS), Sanofi-Aventis (SNY), Genentech (DNA), Bristol Meyers Squibb (BMYS) and many others that are ramping up investments in China, India and Singapore. The company is currently working to establish a separate Chinese operating company that it intends to apply for listing on the Shenzhen or Hong Kong stock exchange.

Biomagnetics is also currently

...

GlaxoSmithKline (GSK) recently received a positive recommendation from the U.S. Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) for its cervical cancer vaccine, Cervarix. The CDC has recommended that Cervarix should be given to girls and young women to protect against cervical pre-cancers and cervical cancer caused by oncogenic human papillomavirus (HPV) 16 and 18.   The committee also recommended that the vaccine should be used in 11 and 12 year old girls specifically and in girls and young women who have not yet been vaccinated. Cervarix, which received approval in the U.S. recently, is indicated for the prevention of cervical pre-cancers and cervical cancer associated with oncogenic HPV types 16 and 18 for use in girls and young women (aged 10-25).   The ACIP’s recommendation should help increase adoption of the vaccine, which is slated to hit the U.S. market later this ...

GlaxoSmithKline (GSK) received good news last week with the receipt of approval from the US Food and Drug Administration (FDA) for its cervical cancer vaccine, Cervarix. The vaccine received approval for the prevention of cervical pre-cancers and cervical cancer associated with oncogenic human papillomavirus (HPV) types 16 and 18 for use in girls and young women (aged 10-25). Last month, an advisory committee of the FDA had voted 12-1 in favor of the efficacy of the vaccine and 11-1 in support of its safety. Cervarix also received approval in Japan for girls aged 10 and above, becoming the first cervical vaccine to gain approval in Japan. The American Cancer Society estimates that about 11,000 women will be diagnosed with cervical cancer and 4,000 women will die from the disease in 2009 in the US. Globally, more than 500,000 women are expected to be diagnosed with cervical ...

Merck (MRK) recently received U.S. Food and Drug Administration (FDA) approval for the use of its vaccine, Gardasil, for the protection of boys and men aged 9–26 years from genital warts related to human papillomavirus (HPV) types 6 and 11. Originally, Gardasil was approved by the FDA in June 2006, as the first vaccine for cervical cancer, (caused by HPV) for females between 9 to 26 years of age.   Earlier, in September, Gardasil received favorable recommendation from the FDA’s advisory panel. The panel voted 7-1 in favor of the vaccine’s safety and 7-0 (with one abstention) regarding its effectiveness. Apart from the favorable recommendation, the panel members expressed their concern about the lack of long-term data, which would have showed the timeframe of effectiveness of the vaccine.   The final approval of the vaccine follows the results of Merck’s phase III studies of Gardasil conducted over a period

...

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Friday October 16, 2009

DrStockPick.com Stock Report!

**************************************************************

Consorteum Holdings, Inc. (OTCBB: CSRH) has launched its mobile check cashing program. The introduction of this service will offer those that are currently using check cashing facilities a much more convenient way to cash their payroll checks. After two years of development with its partners, Consorteum has now proceeded to the pilot phase of its check cashing program in the Toronto, Ontario region. The first stage of the pilot implementation will be the deployment of this new service on

...

GlaxoSmithKline (GSK) is currently awaiting a response from the U.S. Food and Drug Administration (FDA) for its cervical cancer vaccine, Cervarix. Earlier this month, the company received a favorable recommendation from the US Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) for Cervarix.  While the advisory committee voted 12-1 in favor of the efficacy of the vaccine, its safety profile got 11-1 in support from the panel. While the FDA is not bound by the advisory committee’s recommendation, it generally follows the suggestion.  Cervarix was found to be highly effective and was well tolerated in the prevention of cervical pre-cancers and cervical cancer related to human papillomavirus (HPV) types 16 and 18, in girls and young women. Types 16 and 18 are the two most common virus types known to cause cervical cancer.  The vaccine is currently approved in nearly ...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Wednesday September 23, 2009

DrStockPick.com Stock Report!

PWRM, RTN, CVAT, LMT, CSRH, INTU, TSPG, MRK, QGEN

**************************************************************

RTN, Raytheon Company

RTN is a technology and innovation leader specializing in defense, homeland security and other government markets throughout the world.

RTN has surpassed another milestone on its Modernized User Equipment program by achieving live satellite M-code tracking with its MUE receiver. A Raytheon-led team developed modernized versions of the avionics and the ground-based module that receives signals from the Global Positioning System. Delivery of the pre-production receiver to the government is expected in November 2009.

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is

...

Yesterday, GlaxoSmithKline (GSK) received a favorable recommendation from the US Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) for its cervical cancer vaccine, Cervarix.

While the advisory committee voted 12-1 in favor of the efficacy of the vaccine, its safety profile got 11-1 in support from the panel. While the FDA is not bound by the advisory committee’s recommendation, it generally follows the suggestion.

Cervarix was found to be highly effective and was well tolerated in the prevention of cervical pre-cancers and cervical cancer related to human papillomavirus (HPV) types 16 and 18, in girls and young women. Types 16 and 18 are the two most common virus types known to cause cervical cancer.

The vaccine is currently approved in nearly 100 countries around the world, including the 27 member states of the European Union, Australia, Brazil, South Korea, Mexico and Taiwan. Glaxo

...

We await the outcome of the US Food and Drug Administration’s (FDA) advisory panel meeting scheduled for today that will decide on various aspects of human papillomavirus (HPV) vaccines. Primarily there are two vaccines available for the prevention of cervical cancer in women -- Merck’s (MRK) Gardasil and GlaxoSmithKline’s (GSK) Cervarix. Both vaccines are given in a series of three shots over a six-month period. Although Cervarix is approved in several countries, it has yet to gain FDA approval. In June 2006, the FDA approved the first cervical cancer vaccine, Gardasil (which targets four HPV strains: HPV 6, HPV 11, HPV 16 and HPV 18) for females 9 to 26 years of age. The FDA panel will decide on the approval of Cervarix (targets two HPV strains, HPV 16 and HPV 18) in females 10 to 25 years of age. In addition, the vaccine ...

We are pleased to hear that India’s Shantha Biotechnics received a $340 million contract to supply its combination vaccine, SHAN5 for the period of 2010-2012 from a United Nations agency. The vaccine is used for immunizing children against five diseases - Diptheria, Tetanus, Pertussis, Hepatitis B and Hemophilus Influenza B. In July, Sanofi-Aventis’ (SNY) vaccine division Sanofi Pasteur had acquired a 78% stake in Shantha Biotechnics for 550 million Euros ($783 million).

Shantha Biotech has been a prominent player in the vaccine segment for quite some time. It works with several international agencies like the UNICEF in the Asia Pacific, Africa and Latin America. The company is expected to post sales of $90 million in 2009. The deal should be beneficial to both the companies. While Shantha Biotechnics has the resources to produce quality vaccines at cheap rates, being the largest company entirely dedicated to vaccines, Sanofi has

...